Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Imac Holdings ( (BACK) ).
On August 5, 2025, IMAC Holdings issued an unsecured promissory note for $84,000, maturing on December 24, 2025, with a purchase price of $60,000. This financial move includes standard covenants and events of default, impacting the company’s financial operations. Additionally, on August 7, 2025, IMAC Holdings announced a research collaboration with Vanderbilt University Medical Center to advance immuno-oncology biomarker discovery using Ignite Proteomics’ RPPA platform. This collaboration aims to enhance understanding of tumor-immune interactions in breast cancer, potentially refining immunotherapy strategies and benefiting stakeholders by accelerating biomarker discovery.
Spark’s Take on BACK Stock
According to Spark, TipRanks’ AI Analyst, BACK is a Underperform.
IMAC Holdings has a low overall stock score due to significant financial challenges, negative valuation metrics, and technical indicators suggesting weak momentum. The risk of Nasdaq delisting further exacerbates the company’s precarious position. The lack of earnings call data limits further insights into potential strategic actions or improvements.
To see Spark’s full report on BACK stock, click here.
More about Imac Holdings
IMAC Holdings, through its subsidiary Ignite Proteomics, operates in the precision oncology industry, providing pathway-level protein analytics to guide cancer treatment. They utilize a CLIA-certified, CAP-accredited laboratory to perform clinical assays that help match patients with effective targeted and immune therapies.
Average Trading Volume: 14,039
Technical Sentiment Signal: Sell
Current Market Cap: $264.9K
See more insights into BACK stock on TipRanks’ Stock Analysis page.